MX2015014046A - Combinaciones de farmacos para tratar cancer. - Google Patents
Combinaciones de farmacos para tratar cancer.Info
- Publication number
- MX2015014046A MX2015014046A MX2015014046A MX2015014046A MX2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A MX 2015014046 A MX2015014046 A MX 2015014046A
- Authority
- MX
- Mexico
- Prior art keywords
- treat cancer
- drug combinations
- cancer
- treat
- cabozantinib
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 abstract 1
- 229960000853 abiraterone Drugs 0.000 abstract 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001292 cabozantinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808516P | 2013-04-04 | 2013-04-04 | |
| PCT/US2014/033008 WO2014165779A1 (en) | 2013-04-04 | 2014-04-04 | Drug combinations to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015014046A true MX2015014046A (es) | 2016-05-16 |
Family
ID=50732309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014046A MX2015014046A (es) | 2013-04-04 | 2014-04-04 | Combinaciones de farmacos para tratar cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160082019A1 (enExample) |
| EP (1) | EP2983639A1 (enExample) |
| JP (1) | JP2016515628A (enExample) |
| KR (1) | KR20150138268A (enExample) |
| CN (1) | CN108472242A (enExample) |
| AU (1) | AU2014248001A1 (enExample) |
| BR (1) | BR112015025408A8 (enExample) |
| CA (1) | CA2908815A1 (enExample) |
| HK (1) | HK1221424A1 (enExample) |
| MX (1) | MX2015014046A (enExample) |
| WO (1) | WO2014165779A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52754B2 (sr) | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PL2621481T5 (pl) | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| HK1207587A1 (en) | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| EP3738952A1 (en) | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| WO2015142928A1 (en) | 2014-03-17 | 2015-09-24 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| EA034992B1 (ru) | 2014-08-05 | 2020-04-15 | Экселиксис, Инк. | Комбинации лекарственных средств для лечения множественной миеломы |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| MX389966B (es) * | 2017-01-20 | 2025-03-20 | Exelixis Inc | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
| US20200345692A1 (en) * | 2018-01-19 | 2020-11-05 | Indiana University Research And Technology Corporation | Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphoryation in cancer |
| MY210421A (en) | 2018-01-26 | 2025-09-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2392565B1 (en) * | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| JP5368701B2 (ja) * | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| HRP20130961T1 (hr) * | 2006-08-25 | 2013-11-22 | Janssen Oncology, Inc. | Kombinacije za tretman raka |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| RS52754B2 (sr) * | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| EP2454238A1 (en) * | 2009-07-17 | 2012-05-23 | Exelixis, Inc. | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PL2621481T5 (pl) * | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| CN103664778B (zh) * | 2013-11-27 | 2017-04-05 | 苏州摩尔医药有限公司 | 一种抗肿瘤治疗药物卡博替尼的合成方法 |
-
2014
- 2014-04-04 CN CN201480029297.2A patent/CN108472242A/zh active Pending
- 2014-04-04 HK HK16109729.1A patent/HK1221424A1/zh unknown
- 2014-04-04 CA CA2908815A patent/CA2908815A1/en not_active Abandoned
- 2014-04-04 WO PCT/US2014/033008 patent/WO2014165779A1/en not_active Ceased
- 2014-04-04 US US14/782,493 patent/US20160082019A1/en not_active Abandoned
- 2014-04-04 KR KR1020157030445A patent/KR20150138268A/ko not_active Withdrawn
- 2014-04-04 EP EP14724594.8A patent/EP2983639A1/en not_active Withdrawn
- 2014-04-04 JP JP2016506653A patent/JP2016515628A/ja active Pending
- 2014-04-04 BR BR112015025408A patent/BR112015025408A8/pt not_active IP Right Cessation
- 2014-04-04 MX MX2015014046A patent/MX2015014046A/es unknown
- 2014-04-04 AU AU2014248001A patent/AU2014248001A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221424A1 (zh) | 2017-06-02 |
| EP2983639A1 (en) | 2016-02-17 |
| US20160082019A1 (en) | 2016-03-24 |
| JP2016515628A (ja) | 2016-05-30 |
| WO2014165779A1 (en) | 2014-10-09 |
| CA2908815A1 (en) | 2014-10-09 |
| KR20150138268A (ko) | 2015-12-09 |
| AU2014248001A1 (en) | 2015-11-19 |
| BR112015025408A2 (pt) | 2017-07-18 |
| BR112015025408A8 (pt) | 2018-07-10 |
| CN108472242A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2022001105A (es) | Anticuerpos anti tigit. | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
| PH12015501902A1 (en) | Antibody drug conjugates | |
| MX2015011606A (es) | Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX2015011428A (es) | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. | |
| EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| IN2014MU00303A (enExample) | ||
| PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| IN2013MU03118A (enExample) | ||
| GB2546703A (en) | Compounds | |
| MY182434A (en) | Certain chemical entities, compositions, and methods |